2024 ELCC Highlights

CME

Highlights From the 2024 ELCC Annual Congress

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 26, 2024

Expiration: December 25, 2024

Luis Paz-Ares
Luis Paz-Ares, MD, PhD
Zofia Piotrowska
Zofia Piotrowska, MD

Activity

Progress
1 2
Course Completed

References

  1. Yue D, Tan L, Xu S, et al. Surgical outcomes from RATIONALE-315: randomized, double-blind, phase 3 study of perioperative tislelizumab with neoadjuvant chemotherapy in resectable NSCLC. Presented at: European Lung Cancer Congress 2024; March 20-23, 2024. Abstract 108O.
  2. European Medicines Agency. Tizveni. ema.europa.eu/en/medicines/human/EPAR/tizveni. Accessed June 12, 2024.
  3. Spicer JD, Gao S, Liberman M, et al. Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA56.
  4. Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389:491-503.
  5. Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389:1672-1684.
  6. Cascone T, Awad MM, Spicer JD, et al. CheckMate 77T: phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA1.
  7. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.
  8. Girard N, Spicer J, Provencio M, et al. Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816. Presented at: European Lung Cancer Congress 2023; March 1 – April 1, 2023. Abstract 84O.
  9. Yue D, Wang W, Liu H, et al. RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC). Presented at: European Society for Medical Oncology Virtual Plenary 2024; February 15-16, 2024. Abstract VP1-2024.
  10. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823-859.
  11. Zhou C, Huang D, Fan Y, et al. Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): A phase 3, open-label, randomized controlled trial. J Thorac Oncol. 2023;18:93-105.
  12. Tislelizumab [prescribing information]. San Mateo, CA: BeiGene U.S.A., Inc.; 2024.
  13. Pembrolizumab [prescribing information]. Rahway, NJ: Merck Sharpe & Dohme LLC; 2024.
  14. Nivolumab [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2024.
  15. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer. v.5.2024. nccn.org. Accessed June 12, 2024.
  16. Zhou C, Dong X, Chen G, et al. IMpower151: phase III study of atezolizumab + bevacizumab + chemotherapy in 1L metastatic nonsquamous NSCLC. Presented at: 2023 World Conference on Lung Cancer; September 9-12, 2023. Abstract OA09.06.
  17. Jeanson A, Tomasini P, Souquet-Bressand M, et al. Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC). J Thorac Oncol. 2019;14:1095-1101.
  18. Veccia A, Dipasquale M, Kinspergher S, et al. Impact of KRAS mutations on clinical outcomes of patients with advanced non-squamous non-small cell lung cancer receiving anti-PD-1/PD-L1 therapy. Target Oncol. 2023;18:129-138.
  19. Miura Y, Kasahara N, Sunaga N. Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer. Transl Cancer Res. 2019;8:S628-S632.
  20. Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019;30:839-844.
  21. Lin JJ, Chin E, Yeap BY, et al. Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-Small cell lung cancer. J Thorac Oncol. 2019;14:135-140.
  22. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301-1311.
  23. Sakaguchi T, Ito K, Furuhashi K, et al. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria. Respir Investig. 2019;57:466-471.
  24. Eichkorn T, Bozorgmehr F, Regnery S, et al. Consolidation immunotherapy after platinum-based chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer-cross-sectional study of eligibility and administration rates. Front Oncol. 2020;10:586449.
  25. Mountzios MG, Weng J, Zairi E, et al. POSITION: Characterising risk factors and outcomes in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC) who fail to complete concurrent chemoradiotherapy (cCRT) or progress during or shortly after cCRT. Presented at: European Lung Cancer Congress 2024; March 20-23, 2024. Abstract 149P.
  26. Bruni A, Scotti V, Borghetti P, et al. A real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung cancer. Front Oncol. 2021;11:744956.
  27. Hosoya K, Fujimoto D, Kawachi H, et al. Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients. Cancer Chemother Pharmacol. 2019;84:275-280.
  28. Bradley JD, Sugawara S, Lee KHH, et al. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2. Presented at: European Lung Cancer Congress 2024; March 20-23, 2024. Abstract LBA1.
  29. Ernani V, Appiah AK, Baine MJ, Smith LM, Ganti AK. The impact of histology in the outcomes of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) and adjuvant chemotherapy. Cancer Treat Res Commun. 2020;24:100197.
  30. Ball D, Mitchell A, Giroux D, Rami-Porta R, Committee IS, Participating I. Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer. J Thorac Oncol. 2013;8:315-321.
  31. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
  32. Baramidze A, Gessner C, Gogishvili M, et al. Patient-reported outcomes (PROs) of cemiplimab (CEMI) + platinum doublet chemotherapy (CHEMO) + ipilimumab (IPI) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 3 part 1. Presented at: European Lung Cancer Congress 2024; March 20-23, 2024. Abstract 64P.
  33. Baramidze A, Gogishvili M, Melkadze T, et al. Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I. Presented at: European Society for Medical Oncology Immuno-Oncology Congress 2022; December 7-9, 2022. Abstract 122MO.
  34. Food and Drug Administration. FDA approves cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer. fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer. Accessed June 12, 2024.
  35. Food and Drug Administration. FDA approves nivolumab plus ipilimumab and chemotherapy for first-line treatment of metastatic NSCLC. fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc. Accessed June 12, 2024.
  36. Food and Drug Administration. FDA approves tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer. fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non. Accessed June 12, 2024.
  37. Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann Intern Med. 2018;168:121-130.
  38. van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, et al. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease : A cohort study. Ann Intern Med. 2021;174:641-648.
  39. Lusa A, Alvarez C, Saxena Beem S, Schwartz TA, Ishizawar R. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy. BMC Rheumatol. 2022;6:64.
  40. Vidula N, Hutchinson J, McLaren A, et al. Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy. Presented at: 2024 American Society of Clinical Oncology Annual Meeting; May 30 – June 3, 2024. Abstract 1103.
  41. Paz-Ares L, Cappuzzo F, Yamamoto N, et al. Phase Ib/IIa study of ATR inhibitor tuvusertib + anti-PD-1 cemiplimab in patients with advanced non-squamous (nsq) non-small cell lung cancer (NSCLC) that has progressed on prior anti-PD-(L)1 and platinum-based therapies. Presented at: European Lung Cancer Congress 2024; March 20-23, 2024. Abstract 104TiP.
  42. Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7:675-693.
  43. Valdiviezo Lama NI, Okamoto I, Hughes BGM, et al. First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes. Presented at: European Lung Cancer Congress 2024; March 20-23, 2024. Abstract 4O.
  44. Planchard D, Janne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935-1948.
  45. Food and Drug Administration. FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer. fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-chemotherapy-egfr-mutated-non-small-cell-lung-cancer. Accessed June 12, 2024.
  46. Cho BC, Felip E, Spira AI, et al. Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a phase III, global, randomized, controlled trial. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA14.
  47. Planchard D, Jänne PA, Cheng Y, et al. Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC. Presented at: Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA68.
  48. Chiang AC, Madison RW, Huang Y, et al. Validation of a tumor-naïve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC). Presented at: 2024 American Association for Cancer Research Annual Meeting; April 5-10, 2024. Abstract 971.
  49. Bhattarai A, Shah S, Abu Serhan H, Sah R, Sah S. Genomic profiling for non-small cell lung cancer: Clinical relevance in staging and prognosis. Medicine (Baltimore). 2023;102:e36003.
  50. Sito H, Sharzehan MAK, Islam MA, Tan SC. Genetic variants associated with response to platinum-based chemotherapy in non-small cell lung cancer patients: A field synopsis and meta-analysis. Br J Biomed Sci. 2024;81:11835.
  51. Minchom AR, Krebs MG, Cho BC, et al. Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: the PALOMA study—updated safety and identification of the recommended phase 2 dose. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 9126.
  52. Leighl N, Minchom AR, Lee KHH, et al. Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: the phase Ib PALOMA study. Presented at: European Lung Cancer Congress 2024; March 20-23, 2024. Abstract 6MO.
  53. Amivantamab [prescribing information]. Raritan, NJ: Janssen Biotech, Inc.; 2024.
  54. Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35:77-90.
  55. de Speville BD, Moreno V. Antidrug antibodies and drug development: Challenges in the immunotherapy era. Clin Cancer Res. 2021;27:2669-2671.
  56. Hummel H, Champiat S, Olmedo Garcia ME, et al. Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity. Presented at: European Lung Cancer Congress 2024; March 20-23, 2024. Abstract 195MO.
  57. Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27:1526-1537.
  58. Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063-2075.
  59. Paz-Ares L, Champiat S, Lai WV, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study. J Clin Oncol. 2023;41:2893-2903.
  60. Tarlatamab [prescribing information]. Thousand Oaks, CA: Amgen Inc.; 2024.
  61. Food and Drug Administration. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer. Accessed June 12, 2024.
  62. Blackhall F, Girard N, Livartowski A, et al. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study. BMJ Open. 2023;13:e052556.